NOVOVAX VACCINE
No Comments
NOVOVAX VACCINE
Subject : Science & tech
Context : American company Novavax, whose COVID-19 vaccine is set to be made in large numbers by the Pune-based Serum Institute of India (SII), has reported that its vaccine has proved to have 89% efficacy in preventing the infection in some trial volunteers in the United Kingdom.
Concept :
- In January 2020, Novavax announced development of a vaccine candidate, named NVX-CoV2373, to establish immunity to SARS-CoV-2.
- NVX-CoV2373 is a protein subunit vaccine that contains the spike protein of the SARS-CoV-2 virus.
- Novavax’s work is in competition for vaccine development among dozens of other companies.
- The company released phase 3 trials showing that it has 89% efficacy against Covid-19. It also provides strong immunity against new variants. It has applied for emergency use in the US and UK.